Advertising Policy

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy

Advertising Policy

Researchers See Promising Results in Non-Cytotoxic Therapy for Myelodysplastic Syndrome

Using a non-cytotoxic concentration of the DNMT1-inhibitor decitabine to treat myelodysplastic syndrome, Cleveland Clinic researchers were able to increase exposure time for DNMT1 depletion to safely and effectively circumvent p53 mutational apoptotic defects, a cause of resistance to standard treatments. Patients had improved blood counts and extended transfusion-free periods.